芪苈强心胶囊联合大剂量阿托伐他汀对高血压合并动脉粥样硬化患者炎症和血管微循环的影响

目的 探讨芪苈强心胶囊联合大剂量阿托伐他汀对高血压合并动脉粥样硬化患者炎症反应及血管微循环的影响。 方法 选取2015年1月—2018年12月间中国人民解放军第七十二集团军医院收治的192例高血压合并动脉粥样硬化患者，采用随机数字法将患者均分为2组，每组96例。对照组给予阿托伐他汀治疗，联合组在此基础上加用芪苈强心胶囊治疗。治疗后，比较2组炎症反应(hs-CRP、TNF-α、IL-6)、血脂(TG、TC、HDL-C、LDL-C)、血压(SBP、DPB)、血流变(Nbh、Nbl、Np、Fh)、内皮功能(NO、H₂S、ICAM-1)及斑块情况(IMT值、PV)的变化。 结果 治疗后，2组炎症反应、血脂(TG、TC、LDL-C)、血压、血流变均明显降低(均P<0.05)，且联合组均显著低于对照组(均P<0.05)。治疗后，2组HDL-C、NO、H₂S水平显著提高(均P<0.05)，且联合组明显高于对照组(均P<0.05)；2组ICAM-1水平显著降低，且联合组明显低于对照组(均P<0.05)。治疗后，对照组IMT、PV水平无明显变化(均P>0.05)；联合组IMT、PV水平显著降低(均P<0.05)。治疗后联合组的总有效率(88.5%)显著高于对照组(70.8%)，χ2=9.299，P=0.002。 结论 相比于单用阿托伐他汀，芪苈强心胶囊联合大剂量阿托伐他汀可更为有效地减轻高血压合并动脉粥样硬化患者炎症反应，调节患者血管微循环，治疗效果较显著。 

Effect of Qili Qiangxin capsule combined with high-dose atorvastatin on inflammation and vascular microcirculation in patients with hypertension and atherosclerosis

Objective To investigate the effects of Qili Qiangxin capsule combined with high-dose atorvastatin on inflammatory response and vascular microcirculation in patients with hypertension and atherosclerosis. Methods A total of 192 patients with hypertension and atherosclerosis admitted to our hospital from January 2015 to December 2018 were randomly divided into two groups, 96 in each group. The control group was treated with atorvastatin, and the combined group was treated with Qili Qiangxin capsule on this basis. After treatment, inflammatory response (hs-CRP, TNF-α, IL-6), blood lipids (TG, TC, HDL-C, LDL-C), blood pressure (SBP, DPB), hemorheology (Nbh, Nbl, Np, Fh), endothelial function (NO, H₂S, ICAM-1) and changes in plaque conditions (IMT value, PV) were compared between the two groups. Results After treatment, the inflammatory response, blood lipids (TG, TC, LDL-C), blood pressure and hemorheology of two groups were significantly decreased (all P<0.05), and the combination group was significantly lower than the control group (all P<0.05). The levels of HDL-C, NO and H₂S in the two groups were significantly increased (all P<0.05), and the combination group was significantly higher than the control group (all P<0.05). The levels of ICAM-1 in the two groups were significantly decreased, and the combination group was significantly lower than the control group (all P<0.05). After treatment, there was no significant change in IMT and PV levels in the control group (all P>0.05), while IMT and PV levels in the combined group were significantly decreased (all P<0.05). The total effective rate in the combined group (88.5%) was significantly higher than that in the control group (70.8%), χ2=9.299, P=0.002. Conclusion Compared with atorvastatin alone, Qili Qiangxin capsule combined with high-dose atorvastatin can more effectively reduce the inflammatory response and regulate the vascular microcirculation in patients with hypertension and atherosclerosis. The therapeutic effect is more significant.